Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRP | O00591 | 3/20 | 0.41 |
| ▸ | GABRD | O14764 | 3/20 | 0.41 |
| ▸ | GABRA1 | P14867 | 3/20 | 0.41 |
| ▸ | GABRB1 | P18505 | 3/20 | 0.41 |
| ▸ | GABRG2 | P18507 | 3/20 | 0.41 |
| ▸ | GABRB3 | P28472 | 3/20 | 0.41 |
| ▸ | GABRA5 | P31644 | 3/20 | 0.41 |
| ▸ | GABRA3 | P34903 | 3/20 | 0.41 |
| ▸ | GABRA2 | P47869 | 3/20 | 0.41 |
| ▸ | GABRB2 | P47870 | 3/20 | 0.41 |
| ▸ | GABRA4 | P48169 | 3/20 | 0.41 |
| ▸ | GABRE | P78334 | 3/20 | 0.41 |
| ▸ | GABRA6 | Q16445 | 3/20 | 0.41 |
| ▸ | GABRG1 | Q8N1C3 | 3/20 | 0.41 |
| ▸ | GABRG3 | Q99928 | 3/20 | 0.41 |
| ▸ | GABRQ | Q9UN88 | 3/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.39 |
| ▸ | CASP1 | P29466 | 2/20 | 0.39 |
| ▸ | CASP7 | P55210 | 1/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9088819 | 0.69 | DHODH (0.61) | KDM4ECASP1CASP7HSD17B10ALDH1A1 | |
| SCHEMBL17729432 | 0.67 | SMN1; SMN2 (0.39) | KDM4ECASP1CASP7HSD17B10ALDH1A1 | |
| SCHEMBL393852 | 0.66 | GABRP (0.50) | GABRPGABRDGABRA1GABRB1GABRG2 | |
| SCHEMBL631872 | 0.65 | GABRP (0.48) | GABRPGABRDGABRA1GABRB1GABRG2 | |
| SCHEMBL6178995 | 0.64 | DHODH (0.48) | KDM4ECASP1SMN1; SMN2RAB9ADHODH | |
| SCHEMBL25401698 | 0.64 | KDM4E (0.51) | KDM4ECASP1CASP7HSD17B10ALDH1A1 | |
| SCHEMBL25398458 | 0.64 | NAPRT (0.35) | KDM4EALDH1A1SMN1; SMN2RAB9AMAPT | |
| SCHEMBL29524409 | 0.62 | GABRP (0.66) | GABRPGABRDGABRA1GABRB1GABRG2 | |
| SCHEMBL398966 | 0.62 | GABRP (0.66) | GABRPGABRDGABRA1GABRB1GABRG2 | |
| SCHEMBL15530203 | 0.62 | GABRP (0.60) | GABRPGABRDGABRA1GABRB1GABRG2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1440071-B1 | IMIDAZOPYRIDINE COMPOUNDS AS 5-HT 4? RECEPTOR MODULATORS | PFIZER (US) | 2005-10-26 | — | — | EP | disclosed |
| US-20040034226-A1 | Imidazopyridine compounds as 5-HT4 receptor modulators | UCHIDA CHIKARA (JP) | 2004-02-19 | — | — | US | disclosed |
| US-6624162-B2 | 5-HT4 receptor binding activity, and thus are useful for the treatment of gastroesophageal reflux disease, non-ulcer dyspepsia, Functional dyspepsia, irritable bowel syndrome or the like in mammalian, especially humans. | PFIZER INC. | 2003-09-23 | — | — | US | disclosed |
| US-20030092699-A1 | Imidazopyridine compounds as 5-HT4 receptor modulators | PFIZER INC. | 2003-05-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030092699-A1 | Imidazopyridine compounds as 5-HT4 receptor modulators | HTR4, HRH4, HRH2 | GABRP 263/4885GABRD 417/4885GABRA1 317/4885 |
| US-20040034226-A1 | Imidazopyridine compounds as 5-HT4 receptor modulators | HRH4, HTR4, HRH2 | GABRP 248/4885GABRD 436/4885GABRA1 316/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.